Zoetis Inc. (ZTS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.00%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.00% | Share-based compensation / revenue. Period ending 2026-06-30. $95.00M ÷ $9.53B × 100 ≈ 1.00% |
| Interest coverage · 12 months | (m) | Operating income ÷ reported interest expense. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 9.53B USD | |
| Stock-based compensation | 95.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | |
| Interest expense · reported / estimated | 238.00M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $9.53B | $95.00M | (m) | $238.00M | (m) | 1.00% | (m) | Reported |
| 2026-03-31 | (m) | $9.53B | $91.00M | (m) | $230.00M | (m) | 0.95% | (m) | Reported |
| 2025-12-31 | (m) | $9.47B | $83.00M | (m) | $222.00M | (m) | 0.88% | (m) | Reported |
| 2025-09-30 | (m) | $9.40B | $80.00M | (m) | $216.00M | (m) | 0.85% | (m) | Reported |
| 2025-06-30 | (m) | $9.38B | $76.00M | (m) | $215.00M | (m) | 0.81% | (m) | Reported |
| 2025-03-31 | (m) | $9.29B | $73.00M | (m) | $221.00M | (m) | 0.79% | (m) | Reported |
| 2024-12-31 | (m) | $9.26B | $74.00M | (m) | $225.00M | (m) | 0.80% | (m) | Reported |
| 2024-09-30 | (m) | $9.15B | $72.00M | (m) | $233.00M | (m) | 0.79% | (m) | Reported |
| 2024-06-30 | (m) | $8.91B | $71.00M | (m) | $235.00M | (m) | 0.80% | (m) | Reported |
| 2024-03-31 | (m) | $8.73B | $69.00M | (m) | $234.00M | (m) | 0.79% | (m) | Reported |
| 2023-12-31 | (m) | $8.54B | $60.00M | (m) | $239.00M | (m) | 0.70% | (m) | Reported |
| 2023-09-30 | (m) | $8.37B | $59.00M | (m) | $242.00M | (m) | 0.70% | (m) | Reported |
| 2023-06-30 | (m) | $8.22B | $57.00M | (m) | $236.00M | (m) | 0.69% | (m) | Reported |
| 2023-03-31 | (m) | $8.09B | $55.00M | (m) | $231.00M | (m) | 0.68% | (m) | Reported |
| 2022-12-31 | (m) | $8.08B | $62.00M | (m) | $221.00M | (m) | 0.77% | (m) | Reported |
| 2022-09-30 | (m) | $8.01B | $60.00M | (m) | $213.00M | (m) | 0.75% | (m) | Reported |
| 2022-06-30 | (m) | $8.00B | $60.00M | (m) | $216.00M | (m) | 0.75% | (m) | Reported |
| 2022-03-31 | (m) | $7.89B | $61.00M | (m) | $220.00M | (m) | 0.77% | (m) | Reported |
| 2021-12-31 | (m) | $7.78B | $58.00M | (m) | $224.00M | (m) | 0.75% | (m) | Reported |
| 2021-09-30 | (m) | $7.62B | $57.00M | (m) | $228.00M | (m) | 0.75% | (m) | Reported |
| 2021-06-30 | (m) | $7.41B | $56.00M | (m) | $234.00M | (m) | 0.76% | (m) | Reported |
| 2021-03-31 | (m) | $7.01B | $56.00M | (m) | $235.00M | (m) | 0.80% | (m) | Reported |
| 2020-12-31 | (m) | $6.67B | $59.00M | (m) | $231.00M | (m) | 0.88% | (m) | Reported |
| 2020-09-30 | (m) | $6.54B | $62.00M | (m) | $229.00M | (m) | 0.95% | (m) | Reported |
| 2020-06-30 | (m) | $6.34B | $64.00M | (m) | $223.00M | (m) | 1.01% | (m) | Reported |
| 2020-03-31 | (m) | $6.34B | $65.00M | (m) | $220.00M | (m) | 1.03% | (m) | Reported |
| 2019-12-31 | (m) | $6.26B | $67.00M | (m) | $223.00M | (m) | 1.07% | (m) | Reported |
| 2019-09-30 | (m) | $6.15B | $68.00M | (m) | $226.00M | (m) | 1.11% | (m) | Reported |
| 2019-06-30 | (m) | $6.05B | $66.00M | (m) | $224.00M | (m) | 1.09% | (m) | Reported |
| 2019-03-31 | (m) | $5.91B | $60.00M | (m) | $215.00M | (m) | 1.01% | (m) | Reported |
| 2018-12-31 | (m) | $5.83B | $53.00M | (m) | $206.00M | (m) | 0.91% | (m) | Reported |
| 2018-09-30 | (m) | $5.72B | $47.00M | (m) | $197.00M | (m) | 0.82% | (m) | Reported |
| 2018-06-30 | (m) | $5.59B | $44.00M | (m) | $186.00M | (m) | 0.79% | (m) | Reported |
| 2018-03-31 | (m) | $5.44B | $44.00M | (m) | $181.00M | (m) | 0.81% | (m) | Reported |
| 2017-12-31 | (m) | $5.31B | $44.00M | (m) | $175.00M | (m) | 0.83% | (m) | Reported |
| 2017-10-01 | (m) | $5.12B | $42.00M | (m) | $166.00M | (m) | 0.82% | (m) | Reported |
| 2017-07-02 | (m) | $5.02B | $40.00M | (m) | $164.00M | (m) | 0.80% | (m) | Reported |
| 2017-04-02 | (m) | $4.96B | $39.00M | (m) | $164.00M | (m) | 0.79% | (m) | Reported |
| 2016-12-31 | (m) | $4.89B | $37.00M | (m) | $166.00M | (m) | 0.76% | (m) | Reported |
| 2016-10-02 | (m) | $4.88B | $40.00M | (m) | $163.00M | (m) | 0.82% | (m) | Reported |
| 2016-07-03 | (m) | $4.86B | $41.00M | (m) | $151.00M | (m) | 0.84% | (m) | Reported |
| 2016-04-03 | (m) | $4.83B | $42.00M | (m) | $139.00M | (m) | 0.87% | (m) | Reported |
| 2015-12-31 | (m) | $4.76B | $43.00M | (m) | $124.00M | (m) | 0.90% | (m) | Reported |
| 2015-09-27 | (m) | $4.81B | $41.00M | (m) | $116.00M | (m) | 0.85% | (m) | Reported |
| 2015-06-28 | (m) | $4.81B | $40.00M | (m) | $116.00M | (m) | 0.83% | (m) | Reported |
| 2015-03-29 | (m) | $4.79B | $37.00M | (m) | $116.00M | (m) | 0.77% | (m) | Reported |
| 2014-12-31 | (m) | $4.79B | $32.00M | (m) | $117.00M | (m) | 0.67% | (m) | Reported |
| 2014-09-28 | (m) | $4.72B | $28.00M | (m) | $117.00M | (m) | 0.59% | (m) | Reported |
| 2014-06-29 | (m) | $4.61B | $25.00M | (m) | $117.00M | (m) | 0.54% | (m) | Reported |
| 2014-03-30 | (m) | $4.57B | $37.00M | (m) | $120.00M | (m) | 0.81% | (m) | Reported |
| 2013-12-31 | (m) | $4.56B | $43.00M | (m) | $113.00M | (m) | 0.94% | (m) | Reported |
| 2013-09-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $4.34B | $28.00M | (m) | $31.00M | (m) | 0.65% | (m) | Reported |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-07-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-04-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $4.23B | $19.00M | (m) | $36.00M | (m) | 0.45% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |